Kinnate Biopharma Inc. (KNTE)
NASDAQ: KNTE
· Real-Time Price · USD
2.65
-0.01 (-0.38%)
At close: Apr 02, 2024, 10:00 PM
Kinnate Biopharma Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 198K | 197K | 201K | 203K | 190K | 184K | 172K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -198K | -197K | -201K | -203K | -190K | -184K | -172K | n/a | n/a | n/a | n/a | n/a |
Operating Income | -19.1M | -33.09M | -34.13M | -34.65M | -32.68M | -31.37M | -27.41M | -27.06M | -26.26M | -24.8M | -21.57M | -17.48M |
Interest Income | 2.24M | n/a | n/a | n/a | 1.12M | n/a | n/a | n/a | 248.00 | 640K | 672K | 403K |
Pretax Income | -17.06M | -30.73M | -31.92M | -32.94M | -31.56M | -30.74M | -27.07M | -26.9M | -26.16M | -24.7M | -21.45M | -17.46M |
Net Income | -17.06M | -30.73M | -31.92M | -31.23M | -29.95M | -30.1M | -26.73M | -26.75M | -26.16M | -24.7M | -21.45M | -17.46M |
Selling & General & Admin | 5.54M | 6.61M | 7.81M | 8.09M | 7.5M | 7.82M | 7.64M | 7.41M | 6.73M | 6.07M | 5.33M | 4.82M |
Research & Development | 13.37M | 24.51M | 26.33M | 26.56M | 25.19M | 23.55M | 19.77M | 19.65M | 19.53M | 18.73M | 16.24M | 12.67M |
Other Expenses | n/a | 1.97M | n/a | n/a | n/a | n/a | n/a | 157K | n/a | n/a | n/a | n/a |
Operating Expenses | 18.91M | 33.09M | 34.13M | 34.65M | 32.68M | 31.37M | 27.41M | 27.06M | 26.26M | 24.8M | 21.57M | 17.48M |
Interest Expense | n/a | n/a | n/a | n/a | 494K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | -198K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 19.1M | 33.09M | 34.13M | 34.65M | 32.68M | 31.37M | 27.41M | 27.06M | 26.26M | 24.8M | 21.57M | 17.48M |
Income Tax Expense | n/a | -197K | n/a | -1.71M | -1.61M | -635K | -337K | -157K | 12K | n/a | n/a | n/a |
Shares Outstanding (Basic) | 47.12M | 47.09M | 46.66M | 45.41M | 44.21M | 44.15M | 44M | 43.88M | 43.66M | 43.66M | 43.54M | 43.48M |
Shares Outstanding (Diluted) | 47.12M | 47.09M | 46.66M | 45.41M | 44.21M | 44.15M | 44M | 43.88M | 43.66M | 43.66M | 43.54M | 43.48M |
EPS (Basic) | -0.36 | -0.65 | -0.68 | -0.69 | -0.68 | -0.68 | -0.61 | -0.61 | -0.6 | -0.57 | -0.49 | -0.4 |
EPS (Diluted) | -0.36 | -0.65 | -0.68 | -0.69 | -0.68 | -0.68 | -0.61 | -0.61 | -0.6 | -0.57 | -0.49 | -0.4 |
EBITDA | -18.91M | -33.09M | -33.93M | -34.45M | -32.49M | -31.19M | -27.23M | -27M | -26.22M | -24.77M | -21.54M | -17.45M |
EBIT | -19.1M | -33.09M | -34.13M | -34.65M | -31.07M | -31.37M | -27.41M | -27.06M | -26.26M | -24.8M | -21.57M | -17.48M |
Depreciation & Amortization | 198K | 197K | 201K | 203K | 190K | 184K | 172K | 58K | 36K | 28K | 28K | 31K |